41/120
1.7 / 5 stars
All 120 Win/Lose results shown below
ALKS Roast Me summary
Alkermes plc. (ALKS). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinALKS / S&P 48.19% / 15.20% |
LoseALKS / S&P 10.79% / 15.00% |
LoseALKS / S&P -81.64% / 50.40% |
| 2026-Q11/3 |
WinALKS / S&P 26.38% / -4.33% |
LoseALKS / S&P 3.21% / 11.30% |
LoseALKS / S&P -56.73% / 27.70% |
| 2025-Q40/3 |
LoseALKS / S&P -6.73% / 2.65% |
LoseALKS / S&P -5.25% / 9.00% |
LoseALKS / S&P -34.10% / 13.40% |
| 2025-Q30/3 |
LoseALKS / S&P 4.86% / 8.12% |
LoseALKS / S&P 1.08% / 4.61% |
LoseALKS / S&P 2.03% / 13.45% |
| 2025-Q21/3 |
LoseALKS / S&P -13.36% / 10.94% |
LoseALKS / S&P -0.17% / 4.83% |
WinALKS / S&P 21.76% / 10.63% |
| 2025-Q11/3 |
WinALKS / S&P 14.81% / -4.27% |
LoseALKS / S&P -12.31% / 4.98% |
LoseALKS / S&P -18.43% / 10.57% |
| 2024-Q41/3 |
WinALKS / S&P 2.75% / 2.41% |
LoseALKS / S&P -6.36% / 5.25% |
LoseALKS / S&P 3.33% / 6.15% |
| 2024-Q32/3 |
WinALKS / S&P 16.14% / 5.89% |
LoseALKS / S&P -5.37% / 5.89% |
WinALKS / S&P 60.16% / 6.11% |
| 2024-Q21/3 |
LoseALKS / S&P -10.97% / 4.28% |
LoseALKS / S&P 3.14% / 5.38% |
WinALKS / S&P 203.57% / 5.12% |
| 2024-Q11/3 |
LoseALKS / S&P -2.42% / 10.56% |
WinALKS / S&P 54.01% / 5.71% |
LoseALKS / S&P ALKS unavailable / 5.59% |
| 2023-Q41/3 |
LoseALKS / S&P -0.96% / 11.69% |
WinALKS / S&P 49.61% / 6.81% |
LoseALKS / S&P ALKS unavailable / 7.78% |
| 2023-Q31/3 |
LoseALKS / S&P -10.51% / -3.27% |
WinALKS / S&P 40.56% / 7.52% |
LoseALKS / S&P ALKS unavailable / -5.03% |
| 2023-Q22/3 |
WinALKS / S&P 11.03% / 8.74% |
WinALKS / S&P 24.60% / 9.50% |
LoseALKS / S&P ALKS unavailable / -8.57% |
| 2023-Q11/3 |
WinALKS / S&P 7.88% / 7.50% |
LoseALKS / S&P -6.66% / 10.77% |
LoseALKS / S&P ALKS unavailable / -15.69% |
| 2022-Q41/3 |
WinALKS / S&P 17.02% / 7.56% |
LoseALKS / S&P -5.28% / 11.88% |
LoseALKS / S&P ALKS unavailable / -17.99% |
| 2022-Q30/3 |
LoseALKS / S&P -25.04% / -4.88% |
LoseALKS / S&P 0.20% / 13.47% |
LoseALKS / S&P ALKS unavailable / -1.41% |
| 2022-Q21/3 |
WinALKS / S&P 13.23% / -16.10% |
LoseALKS / S&P 6.65% / 13.71% |
LoseALKS / S&P ALKS unavailable / 11.04% |
| 2022-Q11/3 |
WinALKS / S&P 13.11% / -4.60% |
LoseALKS / S&P 15.03% / 15.97% |
LoseALKS / S&P ALKS unavailable / 42.23% |
| 2021-Q40/3 |
LoseALKS / S&P -24.58% / 11.03% |
LoseALKS / S&P 13.00% / 15.00% |
LoseALKS / S&P ALKS unavailable / 96.40% |
| 2021-Q31/3 |
WinALKS / S&P 25.77% / 0.58% |
LoseALKS / S&P -3.60% / 10.77% |
LoseALKS / S&P ALKS unavailable / 69.42% |
| 2021-Q21/3 |
WinALKS / S&P 31.26% / 8.55% |
LoseALKS / S&P -5.30% / 6.58% |
LoseALKS / S&P ALKS unavailable / 51.81% |
| 2021-Q10/3 |
LoseALKS / S&P -6.37% / 6.17% |
LoseALKS / S&P -12.57% / -1.06% |
LoseALKS / S&P ALKS unavailable / 7.39% |
| 2020-Q41/3 |
WinALKS / S&P 20.40% / 12.15% |
LoseALKS / S&P -11.29% / -3.72% |
LoseALKS / S&P ALKS unavailable / -33.42% |
| 2020-Q31/3 |
LoseALKS / S&P -14.63% / 8.93% |
WinALKS / S&P 9.08% / -2.04% |
LoseALKS / S&P ALKS unavailable / -27.10% |
| 2020-Q22/3 |
WinALKS / S&P 34.60% / 20.54% |
WinALKS / S&P 8.83% / -0.46% |
LoseALKS / S&P ALKS unavailable / -27.11% |
| 2020-Q11/3 |
LoseALKS / S&P -29.31% / -19.60% |
WinALKS / S&P 9.32% / 3.47% |
LoseALKS / S&P ALKS unavailable / -14.75% |
| 2019-Q41/3 |
LoseALKS / S&P 4.56% / 9.07% |
WinALKS / S&P 7.01% / 5.36% |
LoseALKS / S&P ALKS unavailable / 2.99% |
| 2019-Q30/3 |
LoseALKS / S&P -13.44% / 1.70% |
LoseALKS / S&P 1.91% / 5.02% |
LoseALKS / S&P ALKS unavailable / 0.21% |
| 2019-Q20/3 |
LoseALKS / S&P -38.23% / 4.30% |
LoseALKS / S&P 4.39% / 6.64% |
LoseALKS / S&P ALKS unavailable / 8.65% |
| 2019-Q12/3 |
WinALKS / S&P 23.65% / 13.65% |
WinALKS / S&P 16.60% / 8.12% |
LoseALKS / S&P ALKS unavailable / 14.29% |
| 2018-Q41/3 |
LoseALKS / S&P -30.47% / -13.52% |
WinALKS / S&P 21.13% / 9.05% |
LoseALKS / S&P ALKS unavailable / 18.23% |
| 2018-Q31/3 |
LoseALKS / S&P 3.11% / 7.71% |
WinALKS / S&P 25.24% / 10.21% |
LoseALKS / S&P ALKS unavailable / 19.06% |
| 2018-Q21/3 |
LoseALKS / S&P -28.99% / 3.43% |
WinALKS / S&P 27.12% / 9.03% |
LoseALKS / S&P ALKS unavailable / 14.46% |
| 2018-Q12/3 |
WinALKS / S&P 5.90% / -0.76% |
WinALKS / S&P 19.99% / 7.68% |
LoseALKS / S&P ALKS unavailable / 12.46% |
| 2017-Q42/3 |
WinALKS / S&P 7.65% / 6.64% |
WinALKS / S&P 21.15% / 7.03% |
LoseALKS / S&P ALKS unavailable / 13.82% |
| 2017-Q31/3 |
LoseALKS / S&P -12.30% / 4.48% |
WinALKS / S&P 21.03% / 5.68% |
LoseALKS / S&P ALKS unavailable / 17.57% |
| 2017-Q21/3 |
LoseALKS / S&P -0.91% / 3.09% |
WinALKS / S&P 20.47% / 4.83% |
LoseALKS / S&P ALKS unavailable / 17.74% |
| 2017-Q11/3 |
LoseALKS / S&P 5.25% / 6.07% |
WinALKS / S&P 25.13% / 3.67% |
LoseALKS / S&P ALKS unavailable / 13.32% |
| 2016-Q42/3 |
WinALKS / S&P 18.18% / 3.82% |
WinALKS / S&P 18.68% / 2.09% |
LoseALKS / S&P ALKS unavailable / 7.05% |
| 2016-Q32/3 |
WinALKS / S&P 8.82% / 3.85% |
WinALKS / S&P 8.57% / 0.20% |
LoseALKS / S&P ALKS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ALKS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 63.62% | 20.78% |
| Annualized return | 63.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ALKS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 51.68% | 83.14% |
| Annualized return | 8.69% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ALKS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 5.95% | 319.30% |
| Annualized return | 0.58% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |